XML 44 R37.htm IDEA: XBRL DOCUMENT
v3.25.3

Revenue - Additional Information (Details) - USD ($) | 1 Months Ended | 3 Months Ended | 9 Months Ended
--- | --- | --- | ---
May 31, 2023 | Feb. 28, 2019 | Sep. 30, 2025 | Sep. 30, 2024 | Jun. 30, 2023 | Sep. 30, 2025 | Sep. 30, 2024
Disaggregation Of Revenue [Line Items] |  |  |  |  |  |  |
Revenue from collaboration agreement |  |  | $ 93,973,000 | $ 46,435,000 |  | $ 205,295,000 | $ 131,498,000
Immune Medicine Service Revenue |  |  |  |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |  |  |  |
Revenue from collaboration agreement |  |  | 33,700,000 | 3,500,000 |  | 41,300,000 | 10,000,000
Medicare Reimbursements |  |  |  |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |  |  |  |
Revenue from collaboration agreement |  |  |  | 1,500,000 |  | 7,300,000 | 4,300,000
Medicare Reimbursements | Immune Medicine Service Revenue |  |  |  |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |  |  |  |
Revenue from collaboration agreement |  |  | 2,900,000 |  |  |  |
MRD Development Agreements | Maximum |  |  |  |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |  |  |  |
Additional milestone payment receivable |  |  | 384,000,000 |  |  | 384,000,000 |
Genentech Collaboration Agreement |  |  |  |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |  |  |  |
Revenue from collaboration agreement |  |  |  |  | $ 7,700,000 |  |
Non-refundable upfront payments received |  | $ 300,000,000 |  |  |  | 300,000,000 |
Additional transaction price of regulatory milestone payment | $ 10,000,000 |  |  |  |  |  |
Expected revenue through milestone payments |  |  | 1,800,000,000 |  |  | 1,800,000,000 |
Genentech Collaboration Agreement | Regulatory Milestones |  |  |  |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |  |  |  |
Additional transaction price of regulatory milestone payment | $ 10,000,000 |  |  |  |  |  |
Genentech Collaboration Agreement | Maximum | Regulatory Milestones |  |  |  |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |  |  |  |
Expected revenue through milestone payments |  |  | 65,000,000 |  |  | 65,000,000 |
Genentech Collaboration Agreement | Maximum | Development Milestones |  |  |  |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |  |  |  |
Expected revenue through milestone payments |  |  | 300,000,000 |  |  | 300,000,000 |
Genentech Collaboration Agreement | Maximum | Commercial Milestones |  |  |  |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |  |  |  |
Expected revenue through milestone payments |  |  | $ 1,430,000,000 |  |  | $ 1,430,000,000 |
Cancelled Customer Contracts |  |  |  |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |  |  |  |
Revenue from collaboration agreement |  |  |  |  |  |  | $ 1,100,000
Cancelled Customer Contracts | Immune Medicine Service Revenue |  |  |  |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |  |  |  |
Revenue from collaboration agreement |  |  |  | $ 1,000,000 |  |  |

X
- Definition Additional milestone payment. + References No definition available. + Details
Name: | adpt_AdditionalMilestonePayment
Namespace Prefix: | adpt_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Additional transaction price of regulatory milestone. + References No definition available. + Details
Name: | adpt_AdditionalTransactionPriceOfRegulatoryMilestone
Namespace Prefix: | adpt_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Non-refundable upfront payments received. + References No definition available. + Details
Name: | adpt_NonRefundableUpfrontPaymentsReceived
Namespace Prefix: | adpt_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Revenue recognition milestone method expected milestone receivable. + References No definition available. + Details
Name: | adpt_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable
Namespace Prefix: | adpt_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 + Details
Name: | us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=adpt_ImmuneMedicineServiceRevenueMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=adpt_MedicareReimbursementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=adpt_MRDDevelopmentAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=adpt_GenentechCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=adpt_RegulatoryMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=adpt_DevelopmentMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=adpt_CommercialMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=adpt_CancelledCustomerContractsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |